<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431337</url>
  </required_header>
  <id_info>
    <org_study_id>4993</org_study_id>
    <nct_id>NCT03431337</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate</brief_title>
  <official_title>Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate: A Confirmation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul Sorum, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative-effectiveness study of the treatment of acute bacterial sinusitis with&#xD;
      amoxicillin/clavulanate 875mg/125mg bid for 7 days with or without the addition of&#xD;
      immediate-release amoxicillin 875 mg bid x 7 days. .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind comparative-effectiveness study of the treatment of acute bacterial sinusitis&#xD;
      with standard dose of amoxicillin/clavulanate 875mg/125mg bid for 7 days, as recommended by&#xD;
      the Infectious Disease Society of America, with or without the addition of immediate-release&#xD;
      amoxicillin 875 mg bid x 7 days. The study aims are 1) to confirm, or not, our recent&#xD;
      findings of more rapid improvement in overall symptoms with the additional amoxicillin, but&#xD;
      also of more frequent diarrhea and vaginal yeast infections and 2) to assess, from the&#xD;
      participants' point of view, the balance between improvement and adverse effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility found by interim analysis&#xD;
  </why_stopped>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Ill adult patients coming to a primary care office will be diagnosed by the treating physicians with acute bacterial sinusitis in accordance with the guidelines of the Infectious Disease Society of America.&#xD;
If they do not meet exclusion criteria, they will be offered enrollment in the study.&#xD;
If they agree, they will be provided unlabeled study medication, either amoxicillin/clavulanate 875/125 + placebo pills bid x 7 days (standard dose) or amoxicillin/clavulanate 875/125 + amoxicillin immediate-release 875 (high dose).&#xD;
Outcomes will be assessed, by telephone or over the web (through Qualtrics), at 3 and 10 days after enrollment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Unlabeled bottles of study medications, identified only by participant #, prepared by the pharmacist member of research team. The placebo will be similar in appearance to plain amoxicillin. The pills inside the bottle will be difficult to see until the bottle is opened by the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Global Rating of Improvement of 5 &amp; 6 at the End of 3 Days of Treatment</measure>
    <time_frame>At end of 3 days of treatment</time_frame>
    <description>Rating on a scale of 1=a lot worse, 2=a little worse, 3=the same, 4=a little better, 5=a lot better, 6=no symptoms, with a higher score indicating greater improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Global Rating of Improvement of 5 or 6 at End of 10 Days Since Enrollment</measure>
    <time_frame>At end of 10 days since enrollment</time_frame>
    <description>Rating of 5 (a lot better) or 6 (no symptoms) on Global Rating of Improvement scale, with range of 1 (a lot worse) to 6 (no symptoms), with a higher score indicating greater improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Score on the Sinonasal Outcome Test-16 (SNOT-16) at the End of 3 Days of Treatment</measure>
    <time_frame>At end of 3 days of treatment</time_frame>
    <description>The change between enrollment and the end of 3 days of treatment in the total score on the Sinonasal Outcome Test-16 (SNOT-16). The total SNOT-16 is the sum of the participant's ratings of 16 symptoms of illness on the scale of 0 (no problem) to 3 (severe problem), with a possible range of 0 to 48, with a higher sum indicating more troubling symptoms. A decrease in total score would indicate an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Total Score on the Sinonasal Outcome Test-16 (SNOT-16) at the End of 10 Days Since Enrollment</measure>
    <time_frame>At end of 10 days since enrollment</time_frame>
    <description>The change between enrollment and the end of 10 days since enrollment in the total score on the Sinonasal Outcome Test-16 (SNOT-16). The total SNOT-16 is the sum of the participant's ratings of 16 symptoms of illness on the scale of 0 (no problem) to 3 (severe problem), with a possible range of 0 to 48, with a higher sum indicating more troubling symptoms. A decrease in total score would indicate an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance of Benefits and Detriments</measure>
    <time_frame>At end of 10 days since enrollment</time_frame>
    <description>Assessment of balance between good effects and bad effects of antibiotic on scale of -3=bad effects much greater than good effects to +3=good effects much greater than bad effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Answering &quot;Yes&quot; to Willingness to Take the Antibiotic Again in the Future</measure>
    <time_frame>At end of 10 days since enrollment</time_frame>
    <description>Response of &quot;yes&quot; at the end of 10 days since enrollment to the question whether the participant would take this antibiotic again, with possible answers of yes, no, or uncertain.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting Any Diarrhea at Day 3 Among Those Self-identified as Prone or Not Prone to Diarrhea</measure>
    <time_frame>At the end of 3 days</time_frame>
    <description>Among those who indicated at enrollment whether prone to diarrhea or not, the number giving ratings of 1, 2, or 3 on diarrhea scale ranging from 0 (none) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting Severe Diarrhea at Day 3 Among Those Self-identified as Prone or Not Prone to Diarrhea</measure>
    <time_frame>At end of day 3</time_frame>
    <description>Among those reporting proneness to diarrhea or not at enrollment, the number rating 3 on diarrhea scale ranging from 0 (none) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting Any Diarrhea at Day 10 Among Those Self-identified as Prone or Not Prone to Diarrhea</measure>
    <time_frame>At 10 days since enrollment</time_frame>
    <description>Among those indicating at enrollment a proneness or not to diarrhea, the number giving ratings of 1, 2, or 3 on the diarrhea scale ranging from 0 (none) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting Severe Diarrhea at Day 10 Among Those Self-identified as Prone or Not Prone to Diarrhea</measure>
    <time_frame>At 10 days since enrollment</time_frame>
    <description>Among those indicating proneness to diarrhea or not at enrollment, the number who gave a rating of 3 on the diarrhea scale ranging from 0 (none) to 3 (severe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Female Participants Reporting Any Vaginal Symptoms at Day 3 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</measure>
    <time_frame>After 3 days of treatment</time_frame>
    <description>Female participants contacted after 3 days of treatment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave ratings of 1, 2, or 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Female Participants Reporting Severe Vaginal Symptoms at Day 3 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</measure>
    <time_frame>At the end of 3 days of treatment</time_frame>
    <description>Among female participants indicating a proneness or not to vaginal itching or discharge, the number of ratings of 3 on the vaginal symptom scale ranging from 0 (none) to 3 (severe)Female participants contacted after 3 days of treatment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave a rating of 1, 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Female Participants Reporting Any Vaginal Symptoms at Day 10 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</measure>
    <time_frame>At 10 days since enrollment</time_frame>
    <description>Female participants contacted after 10 days since enrollment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave ratings of 1, 2, or 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Female Participants Reporting Severe Vaginal Symptoms at Day 10 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</measure>
    <time_frame>At 10 days since enrollment</time_frame>
    <description>Female participants contacted at 10 days since enrollment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave rating of 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Sinusitis, Acute</condition>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin/clavulanate 875mg/125mg &amp; amoxicillin 875 mg twice a day x 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin/clavulanate 875 mg/125mg &amp; placebo (lactase) twice a day x 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin 875 mg</intervention_name>
    <description>Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125</description>
    <arm_group_label>High dose</arm_group_label>
    <other_name>Amoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (lactase)</intervention_name>
    <description>Placebo (in place of additional amoxicillin in experimental arm)</description>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 and older who are patients at the Albany Medical Center Internal Medicine&#xD;
             and Pediatrics practice (study site).&#xD;
&#xD;
          2. Clinical diagnosis of acute bacterial sinusitis in accordance with the guidelines of&#xD;
             the Infectious Disease Society of America (fitting into one of 3 categories:&#xD;
             persistent sinus symptoms for 10 days or more; severe sinus symptoms for 3 days or&#xD;
             more; or worsening sinus symptoms after initial improvement (double sickening).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous enrollment in the current study&#xD;
&#xD;
          2. Allergy or intolerance to any penicillin or to amoxicillin/clavulanate&#xD;
&#xD;
          3. Serious hypersensitivity reaction to any beta lactam&#xD;
&#xD;
          4. Elevated risk of amoxicillin-resistant bacteria: a. amoxicillin, penicillin, or other&#xD;
             beta-lactam within the past month; b. known to have had methicillin-resistant Staph&#xD;
             aureus&#xD;
&#xD;
          5. Chronic or recurrent &quot;sinus&quot; problems (defined as a) persistent symptoms of &quot;sinus&quot;&#xD;
             congestion, not attributed to nasal allergies, for 8 weeks or more or b) 2 or more&#xD;
             episodes of antibiotic-treated &quot;sinusitis&quot; in past 3 months&#xD;
&#xD;
          6. Need to use high-dose amoxicillin/clavulanate or levofloxacin or to send to emergency&#xD;
             department or to hospitalize because of a) signs of severe infection or b)&#xD;
             immunocompromise&#xD;
&#xD;
          7. Cognitive impairment, so unable to give reliable symptom ratings (even if a health&#xD;
             proxy can give consent)&#xD;
&#xD;
          8. Pregnant women and nursing mothers&#xD;
&#xD;
          9. Drug warnings: a) taking allopurinol; b) current mononucleosis; c) chronic kidney&#xD;
             disease stage 4 (estimated glomerular filtration rate &lt;30); d) hepatic impairment (not&#xD;
             including isolated transaminase elevated &lt; 2 times upper limit of normal); e) history&#xD;
             of antibiotic-associated colitis (C. difficile)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul C Sorum, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albany Medical Center Internal Medicine and Pediatrics</name>
      <address>
        <city>Cohoes</city>
        <state>New York</state>
        <zip>12047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, Pankey GA, Seleznick M, Volturo G, Wald ER, File TM Jr; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012 Apr;54(8):e72-e112. doi: 10.1093/cid/cir1043. Epub 2012 Mar 20.</citation>
    <PMID>22438350</PMID>
  </reference>
  <reference>
    <citation>Lemiengre MB, van Driel ML, Merenstein D, Young J, De Sutter AI. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database Syst Rev. 2012 Oct 17;10:CD006089. doi: 10.1002/14651858.CD006089.pub4. Review. Update in: Cochrane Database Syst Rev. 2018 Sep 10;9:CD006089.</citation>
    <PMID>23076918</PMID>
  </reference>
  <reference>
    <citation>Canafax DM, Yuan Z, Chonmaitree T, Deka K, Russlie HQ, Giebink GS. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J. 1998 Feb;17(2):149-56.</citation>
    <PMID>9493813</PMID>
  </reference>
  <reference>
    <citation>Wald ER, Nash D, Eickhoff J. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics. 2009 Jul;124(1):9-15. doi: 10.1542/peds.2008-2902.</citation>
    <PMID>19564277</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <results_first_submitted>January 2, 2021</results_first_submitted>
  <results_first_submitted_qc>July 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Paul Sorum, MD</investigator_full_name>
    <investigator_title>Professor of Internal Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD will be made available to other researchers by contacting the corresponding author at sorump@amc.edu.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediately and indefinitely</ipd_time_frame>
    <ipd_access_criteria>Contact the corresponding author at sorump@amc.edu</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03431337/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose</title>
          <description>Amoxicillin/clavulanate 875mg/125mg &amp; amoxicillin 875 mg twice a day x 7 days&#xD;
Amoxicillin 875 mg: Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125</description>
        </group>
        <group group_id="P2">
          <title>Standard Dose</title>
          <description>Amoxicillin/clavulanate 875 mg/125mg &amp; placebo (lactase) twice a day x 7 days.&#xD;
Placebo (lactase): Placebo (in place of additional amoxicillin in experimental arm)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose</title>
          <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
        </group>
        <group group_id="B2">
          <title>Standard Dose</title>
          <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="15.8"/>
                    <measurement group_id="B2" value="48.5" spread="16.2"/>
                    <measurement group_id="B3" value="48.5" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking (No. [%]</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma or COPD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Allergic rhinitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of sinusitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospitalized in past month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antibiotics in past month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Using nasal steroids</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Enrolled in previous study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days of illness prior to enrollment</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="6.0"/>
                    <measurement group_id="B2" value="17.1" spread="11.0"/>
                    <measurement group_id="B3" value="15.4" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinusitis category 1 (duration 10 days or greater)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinusitis category 2 (severe symptoms)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinusitis category 3 (double sickening)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinonasal Outcome Test-16 total score</title>
          <description>Sum of the ratings of 16 symptoms of illness on the scale of 0 (no problem) to 3 (severe problem), with a possible range of 0 to 48, with a higher sum indicating more troubling symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="7.4"/>
                    <measurement group_id="B2" value="29.4" spread="8.0"/>
                    <measurement group_id="B3" value="29.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tend to be constipated</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prone to diarrhea</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tend to get vaginal yeast infections</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="78"/>
                    <count group_id="B2" value="79"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Global Rating of Improvement of 5 &amp; 6 at the End of 3 Days of Treatment</title>
        <description>Rating on a scale of 1=a lot worse, 2=a little worse, 3=the same, 4=a little better, 5=a lot better, 6=no symptoms, with a higher score indicating greater improvement.</description>
        <time_frame>At end of 3 days of treatment</time_frame>
        <population>Participants who provided a Global Rating of Improvement when contacted at the end of 3 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Global Rating of Improvement of 5 &amp; 6 at the End of 3 Days of Treatment</title>
          <description>Rating on a scale of 1=a lot worse, 2=a little worse, 3=the same, 4=a little better, 5=a lot better, 6=no symptoms, with a higher score indicating greater improvement.</description>
          <population>Participants who provided a Global Rating of Improvement when contacted at the end of 3 days of treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Global Rating of Improvement of 5 or 6 at End of 10 Days Since Enrollment</title>
        <description>Rating of 5 (a lot better) or 6 (no symptoms) on Global Rating of Improvement scale, with range of 1 (a lot worse) to 6 (no symptoms), with a higher score indicating greater improvement</description>
        <time_frame>At end of 10 days since enrollment</time_frame>
        <population>Participants who could be reached to give a global rating at the end of 10 days since enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Global Rating of Improvement of 5 or 6 at End of 10 Days Since Enrollment</title>
          <description>Rating of 5 (a lot better) or 6 (no symptoms) on Global Rating of Improvement scale, with range of 1 (a lot worse) to 6 (no symptoms), with a higher score indicating greater improvement</description>
          <population>Participants who could be reached to give a global rating at the end of 10 days since enrollment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Score on the Sinonasal Outcome Test-16 (SNOT-16) at the End of 3 Days of Treatment</title>
        <description>The change between enrollment and the end of 3 days of treatment in the total score on the Sinonasal Outcome Test-16 (SNOT-16). The total SNOT-16 is the sum of the participant's ratings of 16 symptoms of illness on the scale of 0 (no problem) to 3 (severe problem), with a possible range of 0 to 48, with a higher sum indicating more troubling symptoms. A decrease in total score would indicate an improvement in symptoms.</description>
        <time_frame>At end of 3 days of treatment</time_frame>
        <population>Participants who provided a SNOT-16 rating when reached at the end of 3 days</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Score on the Sinonasal Outcome Test-16 (SNOT-16) at the End of 3 Days of Treatment</title>
          <description>The change between enrollment and the end of 3 days of treatment in the total score on the Sinonasal Outcome Test-16 (SNOT-16). The total SNOT-16 is the sum of the participant's ratings of 16 symptoms of illness on the scale of 0 (no problem) to 3 (severe problem), with a possible range of 0 to 48, with a higher sum indicating more troubling symptoms. A decrease in total score would indicate an improvement in symptoms.</description>
          <population>Participants who provided a SNOT-16 rating when reached at the end of 3 days</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="8.8"/>
                    <measurement group_id="O2" value="12.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Total Score on the Sinonasal Outcome Test-16 (SNOT-16) at the End of 10 Days Since Enrollment</title>
        <description>The change between enrollment and the end of 10 days since enrollment in the total score on the Sinonasal Outcome Test-16 (SNOT-16). The total SNOT-16 is the sum of the participant's ratings of 16 symptoms of illness on the scale of 0 (no problem) to 3 (severe problem), with a possible range of 0 to 48, with a higher sum indicating more troubling symptoms. A decrease in total score would indicate an improvement in symptoms.</description>
        <time_frame>At end of 10 days since enrollment</time_frame>
        <population>Participants who could be reached at 10 days since enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total Score on the Sinonasal Outcome Test-16 (SNOT-16) at the End of 10 Days Since Enrollment</title>
          <description>The change between enrollment and the end of 10 days since enrollment in the total score on the Sinonasal Outcome Test-16 (SNOT-16). The total SNOT-16 is the sum of the participant's ratings of 16 symptoms of illness on the scale of 0 (no problem) to 3 (severe problem), with a possible range of 0 to 48, with a higher sum indicating more troubling symptoms. A decrease in total score would indicate an improvement in symptoms.</description>
          <population>Participants who could be reached at 10 days since enrollment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="11.4"/>
                    <measurement group_id="O2" value="21.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Balance of Benefits and Detriments</title>
        <description>Assessment of balance between good effects and bad effects of antibiotic on scale of -3=bad effects much greater than good effects to +3=good effects much greater than bad effects</description>
        <time_frame>At end of 10 days since enrollment</time_frame>
        <population>Participants who could be reached to assess their treatment at 10 days since enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Balance of Benefits and Detriments</title>
          <description>Assessment of balance between good effects and bad effects of antibiotic on scale of -3=bad effects much greater than good effects to +3=good effects much greater than bad effects</description>
          <population>Participants who could be reached to assess their treatment at 10 days since enrollment</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.8"/>
                    <measurement group_id="O2" value="2.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Answering &quot;Yes&quot; to Willingness to Take the Antibiotic Again in the Future</title>
        <description>Response of &quot;yes&quot; at the end of 10 days since enrollment to the question whether the participant would take this antibiotic again, with possible answers of yes, no, or uncertain.</description>
        <time_frame>At end of 10 days since enrollment</time_frame>
        <population>Participants who could be reached at day 10 to assess their treatment</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose</title>
            <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Answering &quot;Yes&quot; to Willingness to Take the Antibiotic Again in the Future</title>
          <description>Response of &quot;yes&quot; at the end of 10 days since enrollment to the question whether the participant would take this antibiotic again, with possible answers of yes, no, or uncertain.</description>
          <population>Participants who could be reached at day 10 to assess their treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting Any Diarrhea at Day 3 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
        <description>Among those who indicated at enrollment whether prone to diarrhea or not, the number giving ratings of 1, 2, or 3 on diarrhea scale ranging from 0 (none) to 3 (severe)</description>
        <time_frame>At the end of 3 days</time_frame>
        <population>Participants giving a rating of diarrhea at the end of day 3</population>
        <group_list>
          <group group_id="O1">
            <title>Prone to Diarrhea</title>
            <description>Answering yes to baseline question of whether prone to diarrhea</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Diarrhea</title>
            <description>Answering no to baseline question of whether prone to diarrhea</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Any Diarrhea at Day 3 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
          <description>Among those who indicated at enrollment whether prone to diarrhea or not, the number giving ratings of 1, 2, or 3 on diarrhea scale ranging from 0 (none) to 3 (severe)</description>
          <population>Participants giving a rating of diarrhea at the end of day 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting Severe Diarrhea at Day 3 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
        <description>Among those reporting proneness to diarrhea or not at enrollment, the number rating 3 on diarrhea scale ranging from 0 (none) to 3 (severe)</description>
        <time_frame>At end of day 3</time_frame>
        <population>Participants who indicated whether prone to diarrhea or not at enrollment and then at follow-up rated their diarrhea</population>
        <group_list>
          <group group_id="O1">
            <title>Prone to Diarrhea</title>
            <description>Answering yes to baseline question of whether prone to diarrhea</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Diarrhea</title>
            <description>Answering no to baseline question of whether prone to diarrhea</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Severe Diarrhea at Day 3 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
          <description>Among those reporting proneness to diarrhea or not at enrollment, the number rating 3 on diarrhea scale ranging from 0 (none) to 3 (severe)</description>
          <population>Participants who indicated whether prone to diarrhea or not at enrollment and then at follow-up rated their diarrhea</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting Any Diarrhea at Day 10 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
        <description>Among those indicating at enrollment a proneness or not to diarrhea, the number giving ratings of 1, 2, or 3 on the diarrhea scale ranging from 0 (none) to 3 (severe)</description>
        <time_frame>At 10 days since enrollment</time_frame>
        <population>Participants indicating their adverse effects at 10 days</population>
        <group_list>
          <group group_id="O1">
            <title>Prone to Diarrhea</title>
            <description>Answering yes to baseline question of whether prone to diarrhea</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Diarrhea</title>
            <description>Answering no to baseline question of whether prone to diarrhea</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Any Diarrhea at Day 10 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
          <description>Among those indicating at enrollment a proneness or not to diarrhea, the number giving ratings of 1, 2, or 3 on the diarrhea scale ranging from 0 (none) to 3 (severe)</description>
          <population>Participants indicating their adverse effects at 10 days</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting Severe Diarrhea at Day 10 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
        <description>Among those indicating proneness to diarrhea or not at enrollment, the number who gave a rating of 3 on the diarrhea scale ranging from 0 (none) to 3 (severe)</description>
        <time_frame>At 10 days since enrollment</time_frame>
        <population>Participants who gave ratings of adverse effects at day 10</population>
        <group_list>
          <group group_id="O1">
            <title>Prone to Diarrhea</title>
            <description>Answering yes to baseline question of whether prone to diarrhea</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Diarrhea</title>
            <description>Answering no to baseline question of whether prone to diarrhea</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Severe Diarrhea at Day 10 Among Those Self-identified as Prone or Not Prone to Diarrhea</title>
          <description>Among those indicating proneness to diarrhea or not at enrollment, the number who gave a rating of 3 on the diarrhea scale ranging from 0 (none) to 3 (severe)</description>
          <population>Participants who gave ratings of adverse effects at day 10</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Female Participants Reporting Any Vaginal Symptoms at Day 3 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
        <description>Female participants contacted after 3 days of treatment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave ratings of 1, 2, or 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
        <time_frame>After 3 days of treatment</time_frame>
        <population>Female participants available at the end of 3 days of treatment who had indicated proneness or not to vaginal symptoms at enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating proneness to vaginal itching or discharge at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating no proneness to vaginal itching or discharge at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Participants Reporting Any Vaginal Symptoms at Day 3 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
          <description>Female participants contacted after 3 days of treatment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave ratings of 1, 2, or 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
          <population>Female participants available at the end of 3 days of treatment who had indicated proneness or not to vaginal symptoms at enrollment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Female Participants Reporting Severe Vaginal Symptoms at Day 3 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
        <description>Among female participants indicating a proneness or not to vaginal itching or discharge, the number of ratings of 3 on the vaginal symptom scale ranging from 0 (none) to 3 (severe)Female participants contacted after 3 days of treatment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave a rating of 1, 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
        <time_frame>At the end of 3 days of treatment</time_frame>
        <population>Female participants reporting adverse effects at day 3</population>
        <group_list>
          <group group_id="O1">
            <title>Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating proneness to vaginal itching or discharge at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating no proneness to vaginal itching or discharge at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Participants Reporting Severe Vaginal Symptoms at Day 3 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
          <description>Among female participants indicating a proneness or not to vaginal itching or discharge, the number of ratings of 3 on the vaginal symptom scale ranging from 0 (none) to 3 (severe)Female participants contacted after 3 days of treatment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave a rating of 1, 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
          <population>Female participants reporting adverse effects at day 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Female Participants Reporting Any Vaginal Symptoms at Day 10 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
        <description>Female participants contacted after 10 days since enrollment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave ratings of 1, 2, or 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
        <time_frame>At 10 days since enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating proneness to vaginal itching or discharge at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating no proneness to vaginal itching or discharge at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Participants Reporting Any Vaginal Symptoms at Day 10 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
          <description>Female participants contacted after 10 days since enrollment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave ratings of 1, 2, or 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Female Participants Reporting Severe Vaginal Symptoms at Day 10 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
        <description>Female participants contacted at 10 days since enrollment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave rating of 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
        <time_frame>At 10 days since enrollment</time_frame>
        <population>Female participants giving ratings of adverse effects at day 10</population>
        <group_list>
          <group group_id="O1">
            <title>Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating proneness to vaginal itching or discharge at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Not Prone to Vaginal Itching or Discharge</title>
            <description>Female participants indicating no proneness to vaginal itching or discharge at enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Participants Reporting Severe Vaginal Symptoms at Day 10 Among Those Self-identified as Prone or Not Prone to Vaginal Itching or Discharge</title>
          <description>Female participants contacted at 10 days since enrollment were divided into two groups: those who had or had not reported at baseline a proneness to vaginal symptoms. The measure was the number in each group who gave rating of 3 on the vaginal symptoms scale, ranging from 0 (none) to 3 (severe), with a higher score indicating more severe symptoms.</description>
          <population>Female participants giving ratings of adverse effects at day 10</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days since enrollment</time_frame>
      <desc>Participants were asked about adverse events at the end of 3 and 10 days. Since they were are office patients, we would have been aware of deaths or serious adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>Amoxicillin 875 mg/clavulanate 125 mg + amoxicillin 875 mg twice a day x 7 days</description>
        </group>
        <group group_id="E2">
          <title>Standard Dose</title>
          <description>Amoxicillin 875 mg/clavulanate 125 mg + placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe diarrhea at day 3</sub_title>
                <description>Rating of 3 on a diarrhea scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Any diarrhea day 3</sub_title>
                <description>Rating of 1, 2, or 3 on a diarrhea scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="65"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Severe diarrhea day 10</sub_title>
                <description>Rating of 3 on a diarrhea scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Any diarrhea day 10</sub_title>
                <description>Score of 1, 2, or 3 on a diarrhea scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Severe vaginal itching or discharge day 3</sub_title>
                <description>Rating of 3 on vaginal symptom scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Any vaginal itching or discharge day 3</sub_title>
                <description>Rating of 1, 2, or 3 on vaginal symptom scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Severe vaginal discharge or itching day 10</sub_title>
                <description>Score of 3 on vaginal symptoms scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Any vaginal itching or discharge day 10</sub_title>
                <description>Score of 1, 2, or 3 on vaginal symptom scale ranging from 0 (none) to 3 (severe)</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination midway in the study after a preliminary analysis demonstrated futility&#xD;
Underestimation of non-serious adverse effects because of dropouts and difficulty contacting participants</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Paul Sorum</name_or_title>
      <organization>Albany Medical College</organization>
      <phone>518-262-7500</phone>
      <email>sorump@amc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

